2008
Advanced Thyroid Cancer Investigational Drug Shows Promise
A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites.
The study was the work of researchers from The University of Texas MD Anderson Cancer Center, and colleagues in 10 other countries, and is published in today’s online issue of the New England Journal of Medicine.
There are few treatment options for patients who have advanced metastatic thyroid cancer (where it has started to spread to other parts of the body) and the prognosis is generally poor. However, thyroid cancer is supported by a protein called VEGF (vascular endothelial growth factor) which helps blood vessels that feed the cancer tumour to grow, so the researchers were keen to find out if a new drug that blocks VEGF might help to slow tumors in thyroid cancer.
Lead author Dr Steven I Sherman, chair and professor of MD Anderson’s Department of Endocrine Neoplasia and Hormonal Disorders, explained the need to find effective treatments for advanced thyroid cancer:
